Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 25021-261

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 25021-261). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Pem04 0000 01)

Chemical structure of Pemetrexed Disodium, showing its molecular arrangement with sodium ions and hydration. The diagram illustrates key functional groups and bonds consistent with the lyophilized powder form used for intravenous injection.*

FDA Label Image

Figure 1 (Pem04 0000 02)

A Kaplan-Meier survival curve depicting overall survival percentage over time in months for two treatment arms involving Pemetrexed. The chart compares P+P+C (solid line) and P+C (dashed line) groups, showing higher survival in the P+P+C arm. The number of patients at risk is tabulated below the x-axis for each time point.*

FDA Label Image

Figure 2 (Pem04 0000 03)

A survival probability curve chart comparing Pemetrexed plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) over a 30-month survival time period. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis represents survival time in months from 0 to 30. Lines show a gradual decrease in survival probability for both treatment groups. A table below the curves lists the number of patients at risk in each group at intervals throughout the study.*

FDA Label Image

Figure 3 (Pem04 0000 04)

A survival probability plot comparing Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) treatments over a 30-month period. The x-axis represents survival time in months, and the y-axis shows survival probability. A table below shows the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 4 (Pem04 0000 05)

A survival curve chart comparing survival probability over time in months for patients treated with Pemetrexed plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC). The x-axis represents survival time in months up to 30 months, and the y-axis represents survival probability from 0 to 1. A table below the graph lists the number of patients at risk for each treatment group at selected time points.*

FDA Label Image

Figure 5 (Pem04 0000 06)

A survival curve graph comparing Pemetrexed injection with placebo over time in months. The y-axis shows survival probability, while the x-axis indicates survival time in months up to 42. The graph includes a table of patients at risk for each group across the time points.*

FDA Label Image

Figure 6 (Pem04 0000 07)

A survival probability plot comparing Pemetrexed and placebo groups over a 42-month period. The solid line represents Pemetrexed, showing higher survival probability over time compared to the dotted placebo line. A table below the x-axis lists the number of patients at risk for both groups at various intervals in months.*

FDA Label Image

Figure 7 (Pem04 0000 08)

A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with Pemetrexed and those given a placebo. The chart includes a table below showing the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 8 (Pem04 0000 09)

A Kaplan-Meier survival curve chart comparing the survival probability over time (in months) between two groups: one treated with Pemetrexed and a placebo group. The chart includes survival probability on the y-axis and survival time in months on the x-axis, with patient numbers at risk displayed below for each time interval.*

FDA Label Image

Figure 9 (Pem04 0000 10)

A survival curve graph comparing survival probability over time in months for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis. A table below lists the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Pem04 0000 11)

Pemetrexed for Injection, USP 100 mg per vial lyophilized powder label. The label states the product is for intravenous use only, single-dose vial. It indicates the drug is cytotoxic and preservative-free, containing pemetrexed disodium equivalent to 100 mg pemetrexed. The label includes storage instructions and the manufacturer, Sagent Pharmaceuticals (USA).*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Pem04 0000 12)

Label for Pemetrexed for Injection, USP, 500 mg per vial, a lyophilized powder for intravenous injection. The label indicates sterile, nonpyrogenic, preservative-free single-dose vial usage. Manufactured by Sagent Pharmaceuticals, with storage instructions and a caution warning about the cytotoxic nature of the agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.